408 related articles for article (PubMed ID: 26187741)
1. Noninferiority of Inhaled Epoprostenol to Inhaled Nitric Oxide for the Treatment of ARDS.
Ammar MA; Bauer SR; Bass SN; Sasidhar M; Mullin R; Lam SW
Ann Pharmacother; 2015 Oct; 49(10):1105-12. PubMed ID: 26187741
[TBL] [Abstract][Full Text] [Related]
2. Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients.
Torbic H; Szumita PM; Anger KE; Nuccio P; LaGambina S; Weinhouse G
J Crit Care; 2013 Oct; 28(5):844-8. PubMed ID: 23683572
[TBL] [Abstract][Full Text] [Related]
3. The Association Between Inhaled Nitric Oxide Treatment and ICU Mortality and 28-Day Ventilator-Free Days in Pediatric Acute Respiratory Distress Syndrome.
Bhalla AK; Yehya N; Mack WJ; Wilson ML; Khemani RG; Newth CJL
Crit Care Med; 2018 Nov; 46(11):1803-1810. PubMed ID: 30028363
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Economic Impact of Formulary Conversion From Inhaled Flolan to Inhaled Veletri for Refractory Hypoxemia in Critically Ill Patients.
Torbic H; Szumita PM; Anger KE; Nuccio P; Lagambina S; Weinhouse G
Ann Pharmacother; 2016 Feb; 50(2):106-12. PubMed ID: 26668204
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness, Safety, and Economic Comparison of Inhaled Epoprostenol Brands, Flolan and Veletri, in Acute Respiratory Distress Syndrome.
Hawn JM; Bauer SR; Wanek MR; Li M; Wang X; Duggal A; Torbic H
Ann Pharmacother; 2020 May; 54(5):434-441. PubMed ID: 31729256
[No Abstract] [Full Text] [Related]
6. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group.
Dellinger RP; Zimmerman JL; Taylor RW; Straube RC; Hauser DL; Criner GJ; Davis K; Hyers TM; Papadakos P
Crit Care Med; 1998 Jan; 26(1):15-23. PubMed ID: 9428538
[TBL] [Abstract][Full Text] [Related]
7. Inhaled epoprostenol improves oxygenation in severe hypoxemia.
Tabrizi MB; Schinco MA; Tepas JJ; Hwang J; Spiwak E; Kerwin AJ
J Trauma Acute Care Surg; 2012 Aug; 73(2):503-6. PubMed ID: 23019678
[TBL] [Abstract][Full Text] [Related]
8. The role of inhaled prostacyclin in treating acute respiratory distress syndrome.
Searcy RJ; Morales JR; Ferreira JA; Johnson DW
Ther Adv Respir Dis; 2015 Dec; 9(6):302-12. PubMed ID: 26294418
[TBL] [Abstract][Full Text] [Related]
9. Inhaled nitric oxide in neonatal and pediatric acute respiratory distress syndrome: dose response, prolonged inhalation, and weaning.
Demirakça S; Dötsch J; Knothe C; Magsaam J; Reiter HL; Bauer J; Kuehl PG
Crit Care Med; 1996 Nov; 24(11):1913-9. PubMed ID: 8917045
[TBL] [Abstract][Full Text] [Related]
10. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure.
Meyer J; Theilmeier G; Van Aken H; Bone HG; Busse H; Waurick R; Hinder F; Booke M
Anesth Analg; 1998 Apr; 86(4):753-8. PubMed ID: 9539597
[TBL] [Abstract][Full Text] [Related]
11. Inhaled nitric oxide and inhaled prostacyclin in acute respiratory distress syndrome: what is the evidence?
Puri N; Dellinger RP
Crit Care Clin; 2011 Jul; 27(3):561-87. PubMed ID: 21742217
[TBL] [Abstract][Full Text] [Related]
12. Use and costs of inhaled nitric oxide and inhaled epoprostenol in adult critically ill patients: A quality improvement project.
Davis SL; Crow JR; Fan JR; Mattare K; Whitman G; Brower RG; Rowden A; Pustavoitau A
Am J Health Syst Pharm; 2019 Sep; 76(18):1413-1419. PubMed ID: 31372630
[TBL] [Abstract][Full Text] [Related]
13. A review of inhaled nitric oxide and aerosolized epoprostenol in acute lung injury or acute respiratory distress syndrome.
Dzierba AL; Abel EE; Buckley MS; Lat I
Pharmacotherapy; 2014 Mar; 34(3):279-90. PubMed ID: 24734313
[TBL] [Abstract][Full Text] [Related]
14. Early administration of inhaled nitric oxide to children with acute respiratory distress syndrome and its effects on oxygenation and ventilator settings: prospective preliminary report of ten patients.
Fioretto JR; Bonatto RC; Ricchetti SM; Carpi MF; de Moraes MA; Padovani CR
Croat Med J; 2001 Oct; 42(5):527-34. PubMed ID: 11596168
[TBL] [Abstract][Full Text] [Related]
15. Severity of Hypoxemia and Other Factors That Influence the Response to Aerosolized Prostacyclin in ARDS.
Kallet RH; Burns G; Zhuo H; Ho K; Phillips JS; Pangilinan LP; Yip V; Gomez A; Lipnick MS
Respir Care; 2017 Aug; 62(8):1014-1022. PubMed ID: 28559468
[TBL] [Abstract][Full Text] [Related]
16. Inhaled aerosolized prostacyclin and nitric oxide as selective pulmonary vasodilators in ARDS--a pilot study.
Van Heerden PV; Blythe D; Webb SA
Anaesth Intensive Care; 1996 Oct; 24(5):564-8. PubMed ID: 8909667
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide versus epoprostenol for refractory hypoxemia in Covid-19.
Poonam PBH; Koscik R; Nguyen T; Rikhi S; Lin HM
PLoS One; 2022; 17(6):e0270646. PubMed ID: 35759496
[TBL] [Abstract][Full Text] [Related]
18. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome.
Zwissler B; Kemming G; Habler O; Kleen M; Merkel M; Haller M; Briegel J; Welte M; Peter K
Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1671-7. PubMed ID: 8970353
[TBL] [Abstract][Full Text] [Related]
19. Inhaled nitric oxide and the risk of renal dysfunction in patients with acute respiratory distress syndrome: a propensity-matched cohort study.
Ruan SY; Wu HY; Lin HH; Wu HD; Yu CJ; Lai MS
Crit Care; 2016 Nov; 20(1):389. PubMed ID: 27903300
[TBL] [Abstract][Full Text] [Related]
20. [Nitric oxide in the treatment of acute respiratory distress syndrome].
Cvachovec K; Romportl D; Havelka Z; Pelichovská M; Hladíková M
Cas Lek Cesk; 2002 May; 141(9):286-90. PubMed ID: 12061198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
